Trial Profile

A Phase I/II Study of RO4893594-PDS in Japanese Patients with Neovascular Age-Related Macular Degeneration and Japanese Patients with Diabetic Macular Edema

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 27 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ranibizumab (Primary)
Indications Diabetic macular oedema; Wet age-related macular degeneration
Focus Adverse reactions; Therapeutic Use
Acronyms TEIEN study
Sponsors Chugai Pharmaceutical

Most Recent Events

27 Nov 2025 New trial record
25 Nov 2025 Results presented in the Chugai pharmaceuticals Media Release.
25 Nov 2025 According to Chugai pharmaceuticals media release, company will file a new drug application in Japan based on the study results.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com